Round Rock Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Round Rock Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-32,438	Closed	-$1.02M	–	313
2026 Q2	$1.02M	Hold	32,438	–	–	0.13%	119
2026 Q1	$803K	Buy	32,438 +81	+0.3%	+$1.93K	0.12%	131
2025 Q4	$755K	Buy	32,357 +7,247	+29%	+$161K	0.11%	143
2025 Q3	$497K	Buy	+25,110	New	+$516K	0.08%	175

Other funds holding CPRX

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Round Rock Advisors's CPRX Position: Q3 2026 in Review

Round Rock Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 32,438 shares — an estimated $1.02M sold.

Round Rock Advisors first reported a position in CPRX in Q3 2025 and held it in 4 quarters. The position peaked at $1.02M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

Round Rock Advisors reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Round Rock Advisors sold 32,438 Catalyst Pharmaceutical shares in Q3 2026, an estimated $1.02M.
Round Rock Advisors first reported a position in Catalyst Pharmaceutical in Q3 2025 and held it in 4 quarters.
Round Rock Advisors's Catalyst Pharmaceutical position peaked at $1.02M in Q2 2026.
2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Round Rock Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.